34 related articles for article (PubMed ID: 35816874)
1. Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein.
Aertgeerts K; Skene R; Yano J; Sang BC; Zou H; Snell G; Jennings A; Iwamoto K; Habuka N; Hirokawa A; Ishikawa T; Tanaka T; Miki H; Ohta Y; Sogabe S
J Biol Chem; 2011 May; 286(21):18756-65. PubMed ID: 21454582
[TBL] [Abstract][Full Text] [Related]
2. Exploring pyrrolidinyl-spirooxindole natural products as promising platforms for the synthesis of novel spirooxindoles as EGFR/CDK2 inhibitors for halting breast cancer cells.
Nafie MS; Al-Majid AM; Ali M; Alayyaf AA; Haukka M; Ashraf S; Ul-Haq Z; El-Faham A; Barakat A
Front Chem; 2024; 12():1364378. PubMed ID: 38487783
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Potent Dual EGFR/HER2 Inhibitors Based on Thiophene Scaffold Targeting H1299 Lung Cancer Cell Line.
Elrayess R; Abdel Aziz YM; Elgawish MS; Elewa M; Yassen ASA; Elhady SS; Elshihawy HA; Said MM
Pharmaceuticals (Basel); 2020 Dec; 14(1):. PubMed ID: 33374155
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of 1-phenyl-tetrahydro-β-carboline-based first dual PRMT5/EGFR inhibitors as potential anticancer agents.
Zhang J; Liu X; Sa N; Zhang JH; Cai YS; Wang KM; Xu W; Jiang CS; Zhu KK
Eur J Med Chem; 2024 Apr; 269():116341. PubMed ID: 38518523
[TBL] [Abstract][Full Text] [Related]
5. Novel Natural Inhibitors for Glioblastoma by Targeting Epidermal Growth Factor Receptor and Phosphoinositide 3-kinase.
Ullah A; Ullah S; Waqas M; Khan M; Rehman NU; Khalid A; Jan A; Aziz S; Naeem M; Halim S; Khan A; Al-Harrasi A
Curr Med Chem; 2024 Apr; ():. PubMed ID: 38616761
[TBL] [Abstract][Full Text] [Related]
6. Revealing Novel Source of Breast Cancer Inhibitors from Seagrass
Prajoko YW; Qhabibi FR; Gerardo TS; Kizzandy K; Tanjaya K; Willyanto SE; Permatasari HK; Surya R; Mayulu N; Taslim NA; Tjandrawinata RR; Syahputra RA; Tallei TE; Tsopmo A; Kim B; Kurniawan R; Nurkolis F
Molecules; 2024 Feb; 29(5):. PubMed ID: 38474594
[No Abstract] [Full Text] [Related]
7.
Situmorang PC; Ilyas S; Syahputra RA; Sari RM; Nugraha AP; Ibrahim A
Front Pharmacol; 2024; 15():1345645. PubMed ID: 38476328
[TBL] [Abstract][Full Text] [Related]
8. Identifying natural products for gastric cancer treatment through pharmacophore creation, 3D QSAR, virtual screening, and molecular dynamics studies.
Jalali Z; Nejad Ebrahimi S; Rezadoost H
Daru; 2023 Dec; 31(2):243-258. PubMed ID: 37733194
[TBL] [Abstract][Full Text] [Related]
9. Protein Kinase Inhibitors as a New Target for Immune System Modulation and Brain Cancer Management.
Filippone A; Mannino D; Casili G; Lanza M; Paterniti I; Cuzzocrea S; Capra AP; Colarossi L; Giuffrida D; Lombardo SP; Esposito E
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555334
[TBL] [Abstract][Full Text] [Related]
10. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies.
Abd El-Meguid EA; Naglah AM; Moustafa GO; Awad HM; El Kerdawy AM
Bioorg Med Chem Lett; 2022 Feb; 58():128529. PubMed ID: 35007724
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor inhibitors as potential anticancer agents: An update of recent progress.
Sharma B; Singh VJ; Chawla PA
Bioorg Chem; 2021 Nov; 116():105393. PubMed ID: 34628226
[TBL] [Abstract][Full Text] [Related]
12. Discovery and evaluation of cytisine N-isoflavones as novel EGFR/HER2 dual inhibitors.
Wang Y; Yin X; Chen L; Yin Z; Zuo Z
Bioorg Chem; 2022 Oct; 127():105868. PubMed ID: 35816874
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and anticancer evaluation of new 4-anilinoquinoline-3-carbonitrile derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers.
Zou M; Li J; Jin B; Wang M; Chen H; Zhang Z; Zhang C; Zhao Z; Zheng L
Bioorg Chem; 2021 Sep; 114():105200. PubMed ID: 34375195
[TBL] [Abstract][Full Text] [Related]
14. Surmounting the resistance against EGFR inhibitors through the development of thieno[2,3-d]pyrimidine-based dual EGFR/HER2 inhibitors.
Milik SN; Abdel-Aziz AK; Lasheen DS; Serya RAT; Minucci S; Abouzid KAM
Eur J Med Chem; 2018 Jul; 155():316-336. PubMed ID: 29902719
[TBL] [Abstract][Full Text] [Related]
15. Discovery of new HER2/EGFR dual kinase inhibitors based on the anilinoquinazoline scaffold as potential anti-cancer agents.
Sadek MM; Serrya RA; Kafafy AH; Ahmed M; Wang F; Abouzid KA
J Enzyme Inhib Med Chem; 2014 Apr; 29(2):215-22. PubMed ID: 23402383
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
